No Clinically Significant Interaction Between Magnesium and Levetiracetam
Magnesium supplementation does not interfere with levetiracetam (Keppra) efficacy or metabolism, and the two can be safely used together. The FDA-approved drug label for levetiracetam explicitly states that it has minimal drug interaction potential, and no interaction with magnesium is documented 1.
Pharmacokinetic Evidence
Levetiracetam has an exceptionally clean drug interaction profile. According to the FDA label, levetiracetam:
- Is not metabolized by cytochrome P450 enzymes
- Does not inhibit or induce hepatic enzymes
- Circulates largely unbound to plasma proteins (<10% bound)
- Does not undergo significant drug-drug interactions through protein binding competition 1
The drug label specifically tested levetiracetam against multiple medications (phenytoin, valproate, oral contraceptives, digoxin, warfarin, probenecid) and found no clinically significant interactions 1. Magnesium is not listed as an interacting substance.
Electrolyte Considerations
While rare case reports document levetiracetam-induced hypokalemia and hypomagnesemia 2, 3, these represent levetiracetam causing electrolyte disturbances rather than magnesium interfering with levetiracetam. One case showed hypokalemia (3.1 mmol/L) and hypomagnesemia (0.56 mmol/L) developing after levetiracetam initiation, which resolved after discontinuation 2. Another case demonstrated refractory hypokalemia that corrected only after switching from levetiracetam to lacosamide 3.
The clinical implication is reversed from the question: levetiracetam may occasionally lower magnesium levels, but magnesium supplementation does not reduce levetiracetam effectiveness.
Potential Therapeutic Synergy
Interestingly, magnesium may actually complement levetiracetam therapy. A retrospective study of 22 patients with drug-resistant epilepsy showed that oral magnesium supplementation (primarily magnesium oxide 420 mg twice daily) significantly reduced seizure frequency from 15.3 to 7.8 seizure days per month over 6-12 months 4. While this study did not specifically examine levetiracetam combinations, it suggests magnesium has independent antiseizure properties through CNS depression mechanisms.
Clinical Recommendations
- Continue both medications without dose adjustment if a patient requires magnesium supplementation while taking levetiracetam
- Monitor electrolytes (potassium and magnesium) periodically in patients on levetiracetam, as the drug itself may cause electrolyte depletion 2, 3
- If refractory hypokalemia or hypomagnesemia develops despite supplementation, consider levetiracetam as the causative agent rather than assuming magnesium malabsorption
- Magnesium supplementation may provide additional seizure control benefit in refractory cases 4
Important Caveat
The only documented interaction involves probenecid, which doubles the metabolite (ucb L057) levels by blocking renal tubular secretion, though this does not affect levetiracetam itself 1. This mechanism is unrelated to magnesium.